[go: up one dir, main page]

WO2008034129A3 - Treatment of cancer or obesity with conjugated linoleic acids - Google Patents

Treatment of cancer or obesity with conjugated linoleic acids Download PDF

Info

Publication number
WO2008034129A3
WO2008034129A3 PCT/US2007/078641 US2007078641W WO2008034129A3 WO 2008034129 A3 WO2008034129 A3 WO 2008034129A3 US 2007078641 W US2007078641 W US 2007078641W WO 2008034129 A3 WO2008034129 A3 WO 2008034129A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
patients
obesity
treatment
conjugated linoleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/078641
Other languages
French (fr)
Other versions
WO2008034129A2 (en
Inventor
Dale E Bauman
Kevin J Harvatine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell Research Foundation Inc
Original Assignee
Cornell Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Research Foundation Inc filed Critical Cornell Research Foundation Inc
Publication of WO2008034129A2 publication Critical patent/WO2008034129A2/en
Publication of WO2008034129A3 publication Critical patent/WO2008034129A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention discloses a method of screening cancer or obesity patients to determine whether the form of cancer or obesity they have is suitable for treatment with conjugated linoleic acids as well as treating patients for cancer based on that determination. The screening identifies patients with tumor cells with a disregulation of lipid metabolism, patients who overexpress the Thyroid Hormone Responsive Spot 14 gene, and patients who overexpress the Sterol Responsive Element Binding Protein gene.
PCT/US2007/078641 2006-09-15 2007-09-17 Treatment of cancer or obesity with conjugated linoleic acids Ceased WO2008034129A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84481506P 2006-09-15 2006-09-15
US60/844,815 2006-09-15

Publications (2)

Publication Number Publication Date
WO2008034129A2 WO2008034129A2 (en) 2008-03-20
WO2008034129A3 true WO2008034129A3 (en) 2008-11-20

Family

ID=39184647

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/078641 Ceased WO2008034129A2 (en) 2006-09-15 2007-09-17 Treatment of cancer or obesity with conjugated linoleic acids

Country Status (1)

Country Link
WO (1) WO2008034129A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012501175A (en) * 2008-08-28 2012-01-19 ネステク ソシエテ アノニム Gene expression profiles associated with lean phenotypes and their use
US8809560B2 (en) 2011-05-17 2014-08-19 Board Of Trustees Of The University Of Arkansas Trans-, trans-conjugated linoleic acid compositions and use thereof
US9375433B2 (en) 2012-09-26 2016-06-28 Tangent Reprofiling Limited Modulators of androgen synthesis
NZ706067A (en) * 2012-09-26 2016-07-29 Tangent Reprofiling Ltd Modulators of androgen synthesis
US9062276B2 (en) 2012-12-03 2015-06-23 Board Of Trustees Of The University Of Arkansas Conjugated linoleic acid rich vegetable oil production from linoleic rich oils by heterogeneous catalysis
CN112569218A (en) * 2020-12-21 2021-03-30 自然资源部第一海洋研究所 Application of conjugated linoleic acid isomer in preparation of medicines and health products for reducing visceral fat content

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BASU S. ET AL.: "Conjugated Linoleic Acid Induces Lipid Peroxidation in Humans", FEBS LETTERS, vol. 468, no. 1, 2000, pages 33 - 36, XP004260993 *

Also Published As

Publication number Publication date
WO2008034129A2 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
WO2008034129A3 (en) Treatment of cancer or obesity with conjugated linoleic acids
WO2007113648A3 (en) Ctla4 antibody combination therapy
WO2008030273A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2007092640A3 (en) Antibodies that bind par-2
WO2008036341A3 (en) Compositions and methods relating to glucagon receptor antibodies
WO2010141596A3 (en) Chemical proteomic assay for optimizing drug binding to target proteins
WO2009098682A3 (en) Methods and compositions for treatment of mitochondrial disorders
EP3241558A3 (en) Highly soluble leptins
WO2008088854A3 (en) Genetic markers for predicting responsiveness to combination therapy
WO2006036922A3 (en) Srage mimetibody, compositions, methods and uses
WO2008092081A3 (en) Targeted delivery of sirna
WO2005040421A3 (en) Prognostic and diagnostic markers for cell proliferative disorders of the breast tissues
WO2006046997A3 (en) Process, system and method for improving the determination of digestive effects upon an ingestable substance
WO2009108706A3 (en) Methods for inhibiting six 1 and eya proteins
WO2009059201A3 (en) Id2 as a target in colorectal carcinoma
WO2007087263A3 (en) Human zip1, zinc and citrate for prostate cancer screening
WO2008047235A3 (en) Methods of treating disorders associated with fat storage
WO2004037198A3 (en) Antibody-mediated induction of tumor cell death
WO2007103876A3 (en) Cancer therapeutic
WO2004007667A3 (en) Polynucleotide and polypeptide fat metabolism regulators and uses thereof
WO2004051269A3 (en) Ciz1 replication protein
WO2006031363A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
TW200716161A (en) Compositions and methods for treating or preventing overweight or obesity with zinc-charged protein fragments
WO2010056630A8 (en) Triazolopyrimidinones and methods of use thereof
WO2008015419A3 (en) Protein solubilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07814885

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07814885

Country of ref document: EP

Kind code of ref document: A2